Human insulin sensitivity after oral sodium butyrate: molecular mechanisms & dependencies

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

Human evidence only

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

In nine lean men, four weeks of 4 g/day oral sodium butyrate was associated with improved peripheral and hepatic insulin sensitivity.
Butyrate → Human insulin sensitivity after oral sodium butyrate source_derived_draftungraded
Experimental context and source evidence
evidence_access
Primary abstract
experimental_model
Uncontrolled before/after pilot with clamp measurements.
limitations
No placebo group; the lean arm cannot establish efficacy in metabolic syndrome.
nutrient_topic
Butyrate collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Butyrate
plain_language
A small human pilot detected a metabolic change in lean participants.
primary_references
Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects. · 2018 · https://pubmed.ncbi.nlm.nih.gov/29799027/ · DOI 10.1038/s41424-018-0025-4
Butyrate: microbial production, fuel use, signaling and nutrient interactions (2026-09-19) · lines 558–564
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Uncontrolled before/after pilot with clamp measurements. · source_derived_draft · unverified_draft
## butyrate-lean-human-insulin A small human pilot detected a metabolic change in lean participants. In nine lean men, four weeks of 4 g/day oral sodium butyrate was associated with improved peripheral and hepatic insulin sensitivity. Model: Uncontrolled before/after pilot with clamp measurements. Limitations: No placebo group; the lean arm cannot establish efficacy in metabolic syndrome. Evidence access: Primary abstract Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects. · 2018 · https://pubmed.ncbi.nlm.nih.gov/29799027/ · DOI 10.1038/s41424-018-0025-4
Complete structured claim and evidence
The same 4 g/day, four-week pilot found no insulin-sensitivity improvement in its ten men with metabolic syndrome.
Butyrate → Human insulin sensitivity after oral sodium butyrate source_derived_draftungraded
Experimental context and source evidence
evidence_access
Primary abstract
experimental_model
Human uncontrolled pilot; separate metabolic-syndrome group.
limitations
Population differences are observed; altered handling is a proposed explanation rather than established mediation.
nutrient_topic
Butyrate collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Butyrate
plain_language
The group with metabolic syndrome did not show the lean-group response.
primary_references
Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects. · 2018 · https://pubmed.ncbi.nlm.nih.gov/29799027/ · DOI 10.1038/s41424-018-0025-4
Butyrate: microbial production, fuel use, signaling and nutrient interactions (2026-09-19) · lines 566–572
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Human uncontrolled pilot; separate metabolic-syndrome group. · source_derived_draft · unverified_draft
## butyrate-metabolic-syndrome-null The group with metabolic syndrome did not show the lean-group response. The same 4 g/day, four-week pilot found no insulin-sensitivity improvement in its ten men with metabolic syndrome. Model: Human uncontrolled pilot; separate metabolic-syndrome group. Limitations: Population differences are observed; altered handling is a proposed explanation rather than established mediation. Evidence access: Primary abstract Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects. · 2018 · https://pubmed.ncbi.nlm.nih.gov/29799027/ · DOI 10.1038/s41424-018-0025-4
Complete structured claim and evidence

The events it takes part in

A mechanism often involves more than two components. These are the full events, with every participant and its role.

Situations it appears in

Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

Open hypotheses

Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.

This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

Human insulin sensitivity after oral sodium butyrate